4//SEC Filing
AMICUS THERAPEUTICS INC 4
Accession 0001209191-15-056046
$FOLDCIK 0001178879operating
Filed
Jun 23, 8:00 PM ET
Accepted
Jun 24, 7:08 PM ET
Size
18.3 KB
Accession
0001209191-15-056046
Insider Transaction Report
Form 4
Valenzano Ken
VP, Pharmacology & Biology
Transactions
- Exercise/Conversion
Stock Options (right to buy)
2015-06-22−5,000→ 21,500 totalExercise: $2.52From: 2014-06-18Exp: 2023-06-18→ Common Stock (5,000 underlying) - Sale
Common stock
2015-06-22$13.85/sh−20,500$284,013→ 27,687 total - Exercise/Conversion
Stock Options (right to buy)
2015-06-22−2,500→ 22,500 totalExercise: $4.16From: 2013-11-01Exp: 2019-11-16→ Common Stock (2,500 underlying) - Exercise/Conversion
Stock Options (right to buy)
2015-06-22−5,000→ 42,500 totalExercise: $2.45From: 2015-01-03Exp: 2024-01-03→ Common Stock (5,000 underlying) - Exercise/Conversion
Common stock
2015-06-22$13.85/sh+20,500$284,013→ 48,187 total - Exercise/Conversion
Stock Options (right to buy)
2015-06-22−5,000→ 15,000 totalExercise: $3.53From: 2014-01-28Exp: 2023-01-28→ Common Stock (5,000 underlying) - Exercise/Conversion
Stock Options (right to buy)
2015-06-22−3,000→ 27,000 totalExercise: $4.38From: 2013-06-04Exp: 2022-06-04→ Common Stock (3,000 underlying)
Footnotes (3)
- [F1]The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2015.
- [F2]This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.60 to $14.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F3]This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.60 to $14.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Documents
Issuer
AMICUS THERAPEUTICS INC
CIK 0001178879
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001178879
Filing Metadata
- Form type
- 4
- Filed
- Jun 23, 8:00 PM ET
- Accepted
- Jun 24, 7:08 PM ET
- Size
- 18.3 KB